News Anthropic sets out its biopharma ambitions in IPO doc Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."
News UK puts £100m into "world-first" AI biosecurity facility The UK government will unveil a big investment package in AI in the Budget this week, headlined by £100m in funding for an AI Biosecurity Lab.
News Novo taps Anthropic's Claude AI for drug discovery Novo adds Anthropic AI models and Claude Science to its drug discovery toolkit in a bid to become "the world's most AI-driven healthcare company."
News Anthropic AI tool conducts physical scientific experiments Anthropic has opened a research preview of its Model Hardware Standard (MHS), the company's first tool designed to operate in the physical world.
News Claude Science outperforms experts in protein binder task Using Claude Science, Claude agents designed high-affinity protein binders for a range of targets, outperforming human experts in some cases.
News Anthropic launches Claude Science for pharma researchers Anthropic had made a big life sciences play with the launch of Claude Science, an AI 'workbench' for researchers involved in drug discovery.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.